Previous Close | 2.8500 |
Open | 2.8700 |
Bid | 2.6400 x 1000 |
Ask | 3.2000 x 1200 |
Day's Range | 2.6100 - 2.8700 |
52 Week Range | 1.3000 - 8.9000 |
Volume | |
Avg. Volume | 375,532 |
Market Cap | 157.735M |
Beta (5Y Monthly) | -0.46 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.7340 |
Earnings Date | Mar 09, 2022 - Mar 14, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 12.14 |
Homology Medicines Inc (NASDAQ: FIXX) announced the details of HMI-204, its optimized, in vivo, one-time gene therapy candidate for metachromatic leukodystrophy (MLD). Following a single I.V. administration in the MLD animal model, the candidate crossed the blood-brain barrier to the central nervous system (CNS) and reached key peripheral organs involved in MLD. Also Read: Homology Medicines Stock Plunges After FDA Clinical Hold On Gene Therapy Trial. Data demonstrated biodistribution to brain r
- Candidate Showed Ability to Target Central Nervous System and Peripheral Organs Following a Single I.V. Administration in MLD Model, a Key Differentiator from Available Treatments and Product Candidates - - Data Demonstrated Biodistribution to Brain Regions and Multiple Cell Types - - Optimizations Included Significant Improvements in Expression, Productivity and Packaging - - Homology Seeks Partner to Advance Development Candidate - BEDFORD, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Homology M
Homology Medicines, Inc. ( NASDAQ:FIXX ) shareholders should be happy to see the share price up 29% in the last...